Ongoing Research

Exploring the Efficacy of Radiopharmaceutical Therapy in the Treatment of Keloids: A Randomized Control Trial

Abstract

Keloids are benign fibroproliferative skin tumors characterized by an excessive deposition of extracellular matrix components. They can cause significant discomfort and aesthetic concerns, leading to diminished quality of life. While various treatments exist, keloids often recur, highlighting the need for more effective therapeutic strategies. This randomized control trial aimed to evaluate the efficacy and safety of P32 radiopharmaceutical therapy in the treatment of keloids.

Phosphorus-32 (P32), a beta-emitting radioisotope, has shown potential in inhibiting excessive fibroblast proliferation, which underlies keloid formation. In this trial, participants with clinically diagnosed keloids were randomly allocated to two groups: one receiving standard care (including corticosteroid injections and silicone sheeting), and the other receiving P32 radiopharmaceutical therapy in addition to standard care.

Treatment outcomes were evaluated based on changes in the size, symptoms, and appearance of the keloids, along with patients’ self-reported satisfaction and quality of life measures. Safety was assessed by monitoring for potential adverse events and systemic absorption of the radioisotope.

Preliminary results indicated that patients treated with P32 radiopharmaceutical therapy demonstrated a significant reduction in keloid size, improved symptoms, and enhanced aesthetic outcomes compared to the standard care group. This improvement was also reflected in higher patient satisfaction scores and better quality of life metrics in the P32 group. The therapy was well-tolerated, with no systemic absorption or significant adverse events observed.

These findings suggest that P32 radiopharmaceutical therapy could offer an effective and safe addition to the therapeutic arsenal against keloids. However, further research in larger populations is needed to confirm these results and explore long-term outcomes, including recurrence rates.